Hostname: page-component-76fb5796d-x4r87 Total loading time: 0 Render date: 2024-04-25T10:25:47.828Z Has data issue: false hasContentIssue false
  • English
  • Français

PET Analysis Indicates Atypical Central Dopamine Receptor Occupancy in Clozapine-Treated Patients

Published online by Cambridge University Press:  06 August 2018

Lars Farde  and
A-L Nordstrom
Lars Farde*
Affiliation:
The Ulf Lundahl Research Unit, Department of Psychiatry and Psychology, The Karolinska Institute, S-104 01 Stockholm, Sweden
A-L Nordstrom
Affiliation:
The Ulf Lundahl Research Unit, Department of Psychiatry and Psychology, The Karolinska Institute, S-104 01 Stockholm, Sweden
*
Correspondence
Get access Rights & Permissions [Opens in a new window]

Abstract

D1 and D2 dopamine (DA) receptor occupancy was determined by PET in the basal ganglia of drug-treated schizophrenic patients. In 22 patients treated with classical neuroleptics at conventional doses, the average D2 occupancy was 78% (s.d. 6%). In five patients treated with the prototype atypical antipsychotic drug clozapine, a lower D2 occupancy of 48% (s.d. 11%, P<0.01) was found. Accordingly, clozapine is ‘atypical’ with respect to the striatal D2 DA receptor occupancy induced in patients. No obvious D1 DA receptor occupancy was induced by the classical neuroleptics haloperidol or sulpiride. The thioxanthene flupenthixol induced a 36-44% D1 occupancy in individual patients. In four patients treated with clozapine the D1 occupancy was 38-52%.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 160 , Issue S17: Clozapine - The Atypical Antipsychotic , May 1992 , pp. 30 - 33
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Ackenheil, M. (1989) Clozapine - pharmacokinetic investigations and biochemical effects in man. Psychopharmacology, 99, S32–S37.CrossRefGoogle ScholarPubMed
American Psychiatric Association (1980) Diagnostic and Statistical Manual of Mental Disorders (3rd edn) (DSM-III). Washington, DC: APA.Google Scholar
Andén, N. E. & Stock, G. (1973) Effect of clozapine on the turnover of dopamine in the corpus striatum and the limbic system. Journal of Pharmacology (London) 25, 346.Google Scholar
Baron, J. C., Martinot, J. L., Cambon, H., et al (1989) Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels. Psychopharmacology, 99, 463–472.Google Scholar
Bergström, M., Boethius, J., Eriksson, L., et al (1981) Head fixation device for reproducible positron alignment in transmission CT and positron emission tomography. Journal of Computer Assisted Tomography, 8, 74–87.Google Scholar
Bondesson, U. & Lindström, L. H. (1988) Determination of clozapine and its N-methylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psychopharmacology, 95, 472–475.Google Scholar
Cambon, H., Baron, J. C., Boulenger, J. P., et al (1987) In vivo assay of neuroleptic receptor binding in the striatum: positron tomography in humans. British Journal of Psychiatry, 151, 824–830.CrossRefGoogle ScholarPubMed
Casey, D. E. (1989) Clozapine: neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology, 99, S47–S53.Google Scholar
ECDEU Manual (1976) Assessment Manual for Psychopharmacology. Washington, DC: US Department of Health, Education and Welfare.Google Scholar
Farde, L., Ehrin, E., Eriksson, L., et al (1985) Substituted benza-mides as ligands for visualizaton of dopamine-D2 receptor binding in the human brain by positron emission tomography. Proceedings of the National Academy of Science (USA), 82, 3863–3867.Google Scholar
Farde, L., Hall, H., Ehrin, S., et al (1986) Quantitative analysis of dopamine-D2 receptor binding in the living human brain by positron emission tomography. Science, 231, 258–261.Google Scholar
Farde, L., Halldin, C., Stone-Elander, S., et al (1987) PET-analysis of human dopamine receptor subtypes using [11C]-SCH23390 and [11C]-raclopride. Psychopharmacology, 92, 278–284.Google Scholar
Farde, L., Wiesel, F.-A., Halldin, C., et al (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Archives of General Psychiatry, 45, 71–78.Google Scholar
Farde, L., Wiesel, F.-A., Nordström, A. L., et al (1989) D1 and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology, 99, S28–S31.CrossRefGoogle ScholarPubMed
Farde, L., Wiesel, F.-A., Halldin, C., et al (1990) D2-dopamine receptor characteristics in neuroleptic-naive patients with schizophrenia - a PET-study with [11C]raclopride. Archives of General Psychiatry, 47, 213–219.CrossRefGoogle Scholar
Halldin, C., Stone-Elander, S., Farde, L., et al (1986) Preparation of [11C] -labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. International Journal of Applied Radiation and Isotopes, 37, 1039–1043.Google Scholar
Halldin, C., Farde, L., H$oUgberg, T., et al (1991) A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. Nuclear Medicine and Biology, 18, 871–881.Google Scholar
Hyttel, J. (1983) SCH23390-the first selective Dopamine-D1 antagonist. European Journal of Pharmacology, 9, 153–154.CrossRefGoogle Scholar
Kane, J., Honigfeld, G., Singer, J., et al (1988) Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry, 45, 789–796.CrossRefGoogle ScholarPubMed
Litton, J., Bergström, L., Eriksson, L., et al (1984) Performance study of the PC-384 positron camera system for emission tomography of the brain. Journal of Computer Assisted Tomography, 8, 74–87.Google Scholar
Ryan, F., Joiner, L., Ryan, A. Jr (1985) The Minitab Handbook (2nd edn). Boston: Duxbury Press.Google Scholar
Shapiro, S. S. & Wilk, M. B. (1972) An analysis of variance test for normality (complete samples). Biometrika, 52, 591.CrossRefGoogle Scholar
Smith, M., Wolf, A. P., Brodie, J. D., et al (1988) Serial [18F]N-methylspiperone PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biological Psychiatry, 23, 653–663.CrossRefGoogle ScholarPubMed
Sokoloff, P., Giros, B., Martres, M. P., et al (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature, 347, 146–151.Google Scholar
Stille, G. & Hippius, H. (1971) Kritische Stellungsnahme zum Begriff der Neuroleptika (anhand von pharmakologischen und klinischen Befunden mit Clozapin). Pharmacopsychiatry, 4, 182–191.Google Scholar
Waddington, J. L. & O'Boyle, K. M. (1989) Drugs acting on brain dopamine receptors: a conceptual re-evaluation five years after the first selective D-l antagonist. Pharmacology and Therapeutics, 43(1), 501–527.Google Scholar
Van Tol, H., Bunzow, J., Guan, H., et al (1991) Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature, 350, 610–614.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.